KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT (2016 - 2025)

Historic EBT for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $9.5 million.

  • Pacira BioSciences' EBT rose 10685.89% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 17617.46%. This contributed to the annual value of -$63.1 million for FY2024, which is 20227.71% down from last year.
  • Per Pacira BioSciences' latest filing, its EBT stood at $9.5 million for Q3 2025, which was up 10685.89% from -$1.9 million recorded in Q2 2025.
  • Pacira BioSciences' EBT's 5-year high stood at $37.9 million during Q2 2023, with a 5-year trough of -$138.9 million in Q3 2024.
  • Its 5-year average for EBT is $4.5 million, with a median of $12.7 million in 2021.
  • Its EBT has fluctuated over the past 5 years, first surged by 70236.83% in 2023, then tumbled by 93643.15% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' EBT stood at -$6.2 million in 2021, then tumbled by 191.51% to -$18.1 million in 2022, then skyrocketed by 286.63% to $33.7 million in 2023, then decreased by 24.3% to $25.5 million in 2024, then tumbled by 62.69% to $9.5 million in 2025.
  • Its EBT was $9.5 million in Q3 2025, compared to -$1.9 million in Q2 2025 and $8.7 million in Q1 2025.